Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15166734 | 0.98 | DUT (0.33) | DUT | |
| SCHEMBL1803181 | 0.91 | HTR1B (0.31) | DUT | |
| SCHEMBL6897953 | 0.91 | KDM4E (0.32) | DUT | |
| SCHEMBL24722777 | 0.89 | — | — | |
| SCHEMBL12804234 | 0.89 | TSHR (0.34) | — | |
| SCHEMBL553913 | 0.89 | HTT (0.34) | DUT | |
| SCHEMBL15863149 | 0.87 | DUT (0.30) | DUT | |
| SCHEMBL31038355 | 0.86 | — | — | |
| SCHEMBL25172928 | 0.86 | KDM4E (0.32) | DUT | |
| SCHEMBL31283347 | 0.86 | DUT (0.38) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268828-A1 | Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides | ORNA THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| WO-2025067464-A1 | HETEROARYL COMPOUND, INTERMEDIATE THEREOF, AND PREPARATION METHOD AND USE THEREFOR | 杭州圣域生物医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119708015-A | Heteroaryl compounds, intermediates, preparation and use thereof | 杭州圣域生物医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4504694-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | Capstan Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119013250-A | Ionizable cationic lipids and lipid nanoparticles | 开普斯坦治疗公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240299311-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240299572-A1 | NITROGEN-CONTAINING COMPOUND, CONJUGATE CONTAINING SAID COMPOUND, AND APPLICATION THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-09-12 | — | — | US | disclosed |
| EP-4408825-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | Orna Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-3480224-B1 | ELECTRO-OPTIC POLYMER | NAT INST INF & COMM TECH (JP) | 2024-06-12 | — | — | EP | disclosed |
| CN-117801107-A | Benzazepine derivatives, conjugates containing same and application thereof | 上海迪诺医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-8859559-B2 | Substituted pyrazines and their use in the treatment of disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| EP-2188276-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | disclosed |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1301497-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004434-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268828-A1 | Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides | ABCB4, CETP, HDLBP | DUT 511/4885 |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | MAPK1, MAP3K2, MAP3K1 | DUT 686/4885 |
| US-20240299572-A1 | NITROGEN-CONTAINING COMPOUND, CONJUGATE CONTAINING SAID COMPOUND, AND APPLICATION THEREOF | TLR8, TLR9, TLR7 | DUT 2128/4885 |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | TOP1, TDP1, TOP2B | DUT 145/4885 |
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | DUT 2209/4885 |
| US-20240299311-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | DUT 1412/4885 |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | DUT 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.